Synopsis
Synopsis
0
JDMF
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Bibr 1048
2. Dabigatran
3. Dabigatran Etexilate
4. Dabigatran Etexilate Mesylate
5. Etexilate Mesylate, Dabigatran
6. Etexilate, Dabigatran
7. Mesylate, Dabigatran Etexilate
8. N-((2-(((4-(aminoiminomethyl)phenyl)amino)methyl)-1-methyl-1h-benzimidazol-5-yl)carbonyl)-n-2-pyridinyl-beta-alanine
9. Pradaxa
1. Dabigatran Etexilate Mesylate
2. 872728-81-9
3. Pradaxa
4. Ethyl 3-[[2-[[4-[(z)-n'-hexoxycarbonylcarbamimidoyl]anilino]methyl]-1-methylbenzimidazole-5-carbonyl]-pyridin-2-ylamino]propanoate;methanesulfonic Acid
5. Dtxsid20236248
6. Ex-a1966
7. Mfcd25424070
8. S5960
9. Ccg-213236
10. Cs-w004358
11. (z)-ethyl 3-(2-(((4-(n'-((hexyloxy)carbonyl)carbamimidoyl)phenyl)amino)methyl)-1-methyl-n-(pyridin-2-yl)-1h-benzo[d]imidazole-5-carboxamido)propanoate Methanesulfonate
12. 728p819
Molecular Weight | 723.8 g/mol |
---|---|
Molecular Formula | C35H45N7O8S |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 11 |
Rotatable Bond Count | 17 |
Exact Mass | 723.30503259 g/mol |
Monoisotopic Mass | 723.30503259 g/mol |
Topological Polar Surface Area | 217 Ų |
Heavy Atom Count | 51 |
Formal Charge | 0 |
Complexity | 1100 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Pradaxa |
PubMed Health | Dabigatran (By mouth) |
Drug Classes | Anticoagulant |
Drug Label | The chemical name for dabigatran etexilate mesylate, a direct thrombin inhibitor, is -Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl] phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfo... |
Active Ingredient | Dabigatran etexilate mesylate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 150mg base; eq 75mg base |
Market Status | Prescription |
Company | Boehringer Ingelheim |
2 of 2 | |
---|---|
Drug Name | Pradaxa |
PubMed Health | Dabigatran (By mouth) |
Drug Classes | Anticoagulant |
Drug Label | The chemical name for dabigatran etexilate mesylate, a direct thrombin inhibitor, is -Alanine, N-[[2-[[[4-[[[(hexyloxy)carbonyl]amino]iminomethyl] phenyl]amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl]-N-2-pyridinyl-,ethyl ester, methanesulfo... |
Active Ingredient | Dabigatran etexilate mesylate |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 150mg base; eq 75mg base |
Market Status | Prescription |
Company | Boehringer Ingelheim |
Pradaxa 75 mg
- Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.
Pradaxa 110 mg
- Primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age 75 years; heart failure (NYHA Class II); diabetes mellitus; hypertension.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
Pradaxa 150 mg
- Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age 75 years; heart failure (NYHA Class II); diabetes mellitus; hypertension.
- Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.
Antithrombins
Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins. (See all compounds classified as Antithrombins.)
B01AE07
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Regulatory Info :
Registration Country : Sweden
Brand Name : Pradaxa
Dosage Form : HARD CAPSULES
Dosage Strength : 150 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Italy
Brand Name : Pradaxa
Dosage Form : Dabigatran 150Mg 60 Units Oral Use
Dosage Strength : 60x1 cps 150 mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Norway
Brand Name : Pradaxa
Dosage Form : Capsule, hard
Dosage Strength : 110 mg
Packaging : Blister, endose
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Pradaxa
Dosage Form : Capsule, hard
Dosage Strength : 150 mg
Packaging : Blister, endose
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Norway
Brand Name : Pradaxa
Dosage Form : Capsule, hard
Dosage Strength : 75 mg
Packaging : Blister, endose
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Italy
Brand Name : PRADAXA
Dosage Form : Hard Capsule
Dosage Strength : 150 mg
Packaging : 60 UNITS 150 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Switzerland
Brand Name : Pradaxa
Dosage Form : Caps
Dosage Strength : 150mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Italy
Brand Name : DABIGATRAN ETEXYLATED DOC
Dosage Form : Hard Capsules
Dosage Strength : 110 mg
Packaging : 30 UNITS 110 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Italy
Brand Name : DABIGATRAN ETEXYLATED EG STADA
Dosage Form : Hard Capsules
Dosage Strength : 150 mg
Packaging : 60 UNITS 150 MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Regulatory Info :
Registration Country : Norway
Brand Name : Dabigatran etexilate Sandoz
Dosage Form : Kapsel, hard
Dosage Strength : 150 mg
Packaging : Boks 60item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
41
PharmaCompass offers a list of Dabigatran Etexilate Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Dabigatran Etexilate Mesylate manufacturer or Dabigatran Etexilate Mesylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dabigatran Etexilate Mesylate manufacturer or Dabigatran Etexilate Mesylate supplier.
PharmaCompass also assists you with knowing the Dabigatran Etexilate Mesylate API Price utilized in the formulation of products. Dabigatran Etexilate Mesylate API Price is not always fixed or binding as the Dabigatran Etexilate Mesylate Price is obtained through a variety of data sources. The Dabigatran Etexilate Mesylate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Dabigatran Etexilate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dabigatran Etexilate, including repackagers and relabelers. The FDA regulates Dabigatran Etexilate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dabigatran Etexilate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dabigatran Etexilate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Dabigatran Etexilate supplier is an individual or a company that provides Dabigatran Etexilate active pharmaceutical ingredient (API) or Dabigatran Etexilate finished formulations upon request. The Dabigatran Etexilate suppliers may include Dabigatran Etexilate API manufacturers, exporters, distributors and traders.
click here to find a list of Dabigatran Etexilate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Dabigatran Etexilate DMF (Drug Master File) is a document detailing the whole manufacturing process of Dabigatran Etexilate active pharmaceutical ingredient (API) in detail. Different forms of Dabigatran Etexilate DMFs exist exist since differing nations have different regulations, such as Dabigatran Etexilate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dabigatran Etexilate DMF submitted to regulatory agencies in the US is known as a USDMF. Dabigatran Etexilate USDMF includes data on Dabigatran Etexilate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dabigatran Etexilate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dabigatran Etexilate suppliers with USDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Dabigatran Etexilate Drug Master File in Korea (Dabigatran Etexilate KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Dabigatran Etexilate. The MFDS reviews the Dabigatran Etexilate KDMF as part of the drug registration process and uses the information provided in the Dabigatran Etexilate KDMF to evaluate the safety and efficacy of the drug.
After submitting a Dabigatran Etexilate KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Dabigatran Etexilate API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Dabigatran Etexilate suppliers with KDMF on PharmaCompass.
A Dabigatran Etexilate CEP of the European Pharmacopoeia monograph is often referred to as a Dabigatran Etexilate Certificate of Suitability (COS). The purpose of a Dabigatran Etexilate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Dabigatran Etexilate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Dabigatran Etexilate to their clients by showing that a Dabigatran Etexilate CEP has been issued for it. The manufacturer submits a Dabigatran Etexilate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Dabigatran Etexilate CEP holder for the record. Additionally, the data presented in the Dabigatran Etexilate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Dabigatran Etexilate DMF.
A Dabigatran Etexilate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Dabigatran Etexilate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Dabigatran Etexilate suppliers with CEP (COS) on PharmaCompass.
A Dabigatran Etexilate written confirmation (Dabigatran Etexilate WC) is an official document issued by a regulatory agency to a Dabigatran Etexilate manufacturer, verifying that the manufacturing facility of a Dabigatran Etexilate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Dabigatran Etexilate APIs or Dabigatran Etexilate finished pharmaceutical products to another nation, regulatory agencies frequently require a Dabigatran Etexilate WC (written confirmation) as part of the regulatory process.
click here to find a list of Dabigatran Etexilate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dabigatran Etexilate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dabigatran Etexilate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dabigatran Etexilate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dabigatran Etexilate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dabigatran Etexilate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dabigatran Etexilate suppliers with NDC on PharmaCompass.
Dabigatran Etexilate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dabigatran Etexilate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dabigatran Etexilate GMP manufacturer or Dabigatran Etexilate GMP API supplier for your needs.
A Dabigatran Etexilate CoA (Certificate of Analysis) is a formal document that attests to Dabigatran Etexilate's compliance with Dabigatran Etexilate specifications and serves as a tool for batch-level quality control.
Dabigatran Etexilate CoA mostly includes findings from lab analyses of a specific batch. For each Dabigatran Etexilate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dabigatran Etexilate may be tested according to a variety of international standards, such as European Pharmacopoeia (Dabigatran Etexilate EP), Dabigatran Etexilate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dabigatran Etexilate USP).